HANA BIOSCIENCES INITIATES TRIAL FOR IPDR
Hana Biosciences has initiated a Phase I IPdR clinical trial in colorectal, gastric, pancreatic and liver cancers. The objectives of this clinical trial are to establish the safety, dose and preliminary efficacy of IPdR in combination with radiation therapy.
IPdR is an orally available, thymidine analogue and prodrug for IUdR, which demonstrated a survival advantage in Phase II studies in anaplastic astrocytoma, a type of brain tumor. Preclinical studies have also demonstrated that IPdR has dose responsive and synergistic effects when combined with radiation in human glioblastoma models. IPdR has also shown superior safety and efficacy compared to IUdR in preclinical studies.